What is Altamira Therapeutics Ltd. (CYTO) stock price today?

Altamira Therapeutics Ltd. (CYTO) is currently trading at $0.30, up 100% today.

What is CYTO P/E ratio?

Altamira Therapeutics Ltd.'s P/E ratio is -0.02. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is CYTO return on equity (ROE)?

Altamira Therapeutics Ltd.'s return on equity (ROE) is -111.64%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is Altamira Therapeutics Ltd.'s market cap?

Altamira Therapeutics Ltd. has a market capitalization of $1.13M.

NASDAQ · Biotechnology

Altamira Therapeutics Ltd. (CYTO) Stock

$0.30 +100.00% NASDAQ: CYTO Healthcare

Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved.

Valuation

Metric	Value
Price	$0.30
Market Cap	$1.13M
P/E Ratio	-0.02
P/B Ratio	0.02
P/S Ratio	0.00
EPS (TTM)	$-14.80
52-Week High	$0.42
52-Week Low	$0.30
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-111.64%
ROA	-84.03%
ROCE	-79.01%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.05
Current Ratio	1.32

Annual Financials (USD)

Metric	2020	2021	2022	2023	2024
Revenue	$0	$0	$0	$0	—
Operating Profit	$-5.0M	$-5.0M	$-18.0M	$-6.0M	—
Net Profit	$-8.0M	$-17.0M	$-27.0M	$-7.0M	—
EPS	$-545.41	$-515.11	$-582.58	$-14.80	—
Op Margin	-3027.9%	-8361.4%	-5894.3%	—	—

Balance Sheet (USD)

Metric	2020	2021	2022	2023	2024
Total Assets	$21.0M	$19.0M	$6.0M	$8.0M	$9.0M
Total Liabilities	$4.0M	$6.0M	$15.0M	$1.0M	$2.0M
Cash	$11.0M	$1.0M	$0	$1.0M	$1.0M
Borrowings	$1.0M	$1.0M	$6.0M	$0	$0

Latest News

CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights PR Newswire · Jul 20, 2026 CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why Zacks · Jul 8, 2026 OTC Markets Life Sciences Investor Forum: Dr. Phillip Chan, CEO, and Pete Mariani, CFO, of CytoSorbents with Zacks SCR’s Tom Kerr, CFA Zacks Small Cap Research · Jul 8, 2026 Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing GlobeNewswire · Jun 26, 2026 Life Sciences Virtual Investor Forum Agenda Announced for June 24th & 25th GlobeNewswire · Jun 23, 2026

Cash Flow (USD)

Metric	2020	2021	2022	2023	2024
Operating Cash Flow	$-5.0M	$-14.0M	$-9.0M	$-12.0M	$-6.0M
Investing Cash Flow	$-5.0M	$-7.0M	$-4.0M	$1.0M	$0
Financing Cash Flow	$15.0M	$7.0M	$4.0M	$10.0M	$7.0M
Net Cash Flow	$10.0M	$-10.0M	$-1.0M	$1.0M	$0
Free Cash Flow	$-7.0M	$-17.0M	$-11.0M	$-12.0M	$-6.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	0.00
EV / EBITDA	-0.09
FCF Yield	-548.42%
Quick Ratio	1.32
Interest Coverage	0.00
Return 1Y	—
Return 3Y	—
Return 5Y	—

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
BLCMBellicum Pharmaceuticals, Inc.	$0.07	-6.68%	-0.09	$778326	0.00%
CWBRCohBar, Inc.	$0.41	+0.00%	-0.10	$1.19M	0.00%
HTGMQHTG Molecular Diagnostics, Inc.	$0.00	—	0.00	$221	0.00%
IMPLImpel Pharmaceuticals Inc.	$0.04	-27.27%	-0.01	$956000	0.00%
INFIQInfinity Pharmaceuticals, Inc.	$0.00	—	0.00	$9076	0.00%

About Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd. is a biotechnology firm dedicated to pioneering new treatments for critical medical needs that are currently underserved. Its marketed offerings include Bentrio, a non-pharmaceutical nasal spray designed for individual protection against prevalent airborne viruses and allergens. The company is also heavily invested in developing RNA therapeutics specifically for extrahepatic targets. This includes their preclinical OligoPhore and SemaPhore platforms, engineered for the effective delivery of oligonucleotides and mRNA. In its clinical-stage portfolio, AM-125 is undergoing Phase II trials for the intranasal treatment of vertigo. Additionally, Keyzilen and Sonsuvi are both in Phase III clinical development; Keyzilen is focused on acute inner ear tinnitus, and Sonsuvi addresses acute inner ear hearing loss. Established in 2003 and headquartered in Hamilton, Bermuda, Altamira Therapeutics conducts operations across Switzerland, the United States, Europe, and Australia. The company officially adopted the name Altamira Therapeutics Ltd. in July 2021, prior to which it was known as Auris Medical Holding Ltd.

Altamira Therapeutics Ltd. is headquartered in BM.

Altamira Therapeutics Ltd. (CYTO) stock trades at $0.30 with a market capitalization of $1.13M. The stock is valued at a price-to-earnings (P/E) ratio of -0.02, price-to-book of 0.02, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.30 and $0.42, and currently trades 28.6% below its 52-week high.

On profitability, Altamira Therapeutics Ltd. generates a return on equity (ROE) of -111.64%, return on capital employed of -79.01%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: altamiratherapeutics.com